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Abstract
Aims To systematically review randomized controlled trials assessing effects of sodium–glucose cotransporter 2 inhibitors
(SGLT2is) on hospitalization for heart failure (HHF) and cardiac structure/function and explore randomized controlled trial
(RCT)-derived evidence for SGLT2i efficacy mechanisms in heart failure (HF).
Methods and results Systematic searches of Medline and Embase were performed. In seven trials [3730–17 160 patients;
low risk of bias (RoB)], SGLT2is significantly reduced the relative risk of HHF by 27–39% vs. placebo, including in two studies
in patients with HF with reduced ejection fraction with or without type-2 diabetes mellitus (T2DM). Improvements in
conventional cardiovascular risk factors, including glycaemic levels, cannot account for these effects. Five trials (56–105
patients; low RoB) assessed the effects of 6–12 months of SGLT2i treatment on left ventricular structure/function; four
reported significant improvements vs. placebo, and one did not. Five trials (low RoB) assessed SGLT2i treatment effects
on serum N-terminal pro B-type natriuretic peptide levels; significant reductions vs. placebo were reported after
8–12 months (two studies; 3730–4744 patients) but not ≤12 weeks (three studies; 80–263 patients). Limited available
RCT-derived evidence suggests various possible cardioprotective SGLT2i mechanisms, including improved haemodynamics
(natriuresis and reduced interstitial fluid without blood volume contraction/neurohormonal activation) and vascular function,
enhanced erythropoiesis, reduced tissue sodium and epicardial fat/inflammation, decreased sympathetic tone, and beneficial
changes in cellular energetics.
Conclusions Sodium–glucose cotransporter 2 inhibitors reduce HHF regardless of T2DM status, and reversal of adverse
left ventricular remodelling likely contributes to this efficacy. Hypothesis-driven mechanistic trials remain sparse, although
numerous trials are planned or ongoing.
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Introduction
In the past 5 years, there has been a profound shift in the
therapeutic focus of trials of sodium–glucose cotransporter
2 inhibitors (SGLT2is). Although initially explored and intro-
duced as glucose-lowering agents for patients with type 2
diabetes mellitus (T2DM),1 clinical investigation of these
molecules has evolved towards heart failure (HF) and chronic
kidney disease (CKD) outcomes in patients with and without
T2DM (Figure 1). This trend has been driven by the impres-
sive cardiac and renal protective properties of SGLT2is, which
are predominantly independent of their glucose-lowering
effects, thus diminishing hyperglycaemia as a prerequisite
condition for their efficacy. Given the unexpected benefits
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of this drug class, it is not surprising that major event-focused
trials have been followed closely by studies exploring the
mechanisms by which SGLT2is may exert their benefits
(Figure 1).
We aimed to systematically review randomized controlled
trial (RCT) data assessing the effects of SGLT2is compared
with placebo on hospitalization for HF (HHF), cardiac
structure and cardiac function. We also aimed to review, in
an exploratory manner, mechanistic evidence for how
SGLT2is may exert their benefits, with a focus on
RCT-derived data. We also identify future trials that may help
to address some of the remaining gaps in the clinical and
mechanistic profiles of these drugs, and briefly discuss the
implications of the current evidence for clinical practice.
Figure 1 Evolution of SGLTi clinical trials over time. Only studies in patients with T2DM, HF, CVD, or CKD are included. We excluded phase 1 trials and
studies assessing PK or safety only. Outcomes being assessed (KEY) by each study were broadly categorized according to the reported primary outcome
for each trial. CVD trials include patients with or at risk of CVD. Major trials including assessments of HF-event outcomes are numbered and described
briefly in the appended table. CKD, chronic kidney disease; CVD, cardiovascular disease; HF, heart failure; T2DM, type 2 diabetes mellitus.
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This systematic review was performed in a Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
compliant manner (Supporting Information, Table S1)
(Figure 2).2 Searches were conducted using terms for ‘so-
dium-glucose cotransporter 2 inhibitors’, ‘heart failure’, ‘car-
diovascular disease’, ‘chronic kidney disease’, and ‘type 2
diabetes mellitus’ (Table S2). Database filters were applied
to exclude congress abstracts, animal studies, reviews, edito-
rials and letters, and to limit searches to studies reported in
English in the past 10 years. Free-text terms (e.g. real-world,
retrospective, and cross-sectional) were used to minimize
identification of non-interventional studies by the targeted
searches. Medline (via PubMed) and Embase (via Ovid) were
searched on 16 August 2020, and results exported separately
to EndNote. After removal of duplicates in EndNote, search re-
sults were combined and exported to Excel for screening. Ti-
tles and abstracts were screened by one author (MMB) and
independently reviewed by a second author (RR).
Study selection
We included RCT studies that assessed the effects of SGLT2is
compared with placebo on HHF events (Table 1) and
subanalyses of these trials (reported in the text only), as well
as RCTs assessing effects of SGLT2is compared with placebo
on cardiac structure and function as primary outcomes, or
as secondary outcomes in large trials (>1000 patients)
(Table 2). We also included RCTs assessing broader potential
mechanisms of SGLT2i efficacy in HF (reported in the text
only). Criteria for broader mechanistic studies were expanded
to include mediation and in silico analyses incorporating RCT
data; however, the wide range of potential mechanisms pro-
posed for SGLT2is precluded an exhaustive account of the lit-
erature. In addition, mechanistic findings are supplemented in
part by opinions held by the authors and wider supporting lit-
erature and should be considered more exploratory in nature.
Data extraction and risk of bias assessments
Extraction of data into tables was performed by a single au-
thor (MMB) and verified by a second author (RR). For trials
assessing HHF, we extracted event rate data, hazard ratios,
95% confidence intervals and P values for the effects of
SGLT2is compared with placebo (Table 1). For trials assessing
cardiac structure and function, we extracted data for mean
changes from baseline in primary outcomes, relevant sum-
mary statistics, and P values, for SGLT2is compared with
placebo (Table 2). We also extracted information relating to
study design (trial type, sample size, follow-up period, etc.)
and relevant baseline patient characteristics (age, sex,
relevant comorbidities and laboratory measures, etc.). A
semi-automated risk of bias (RoB) assessment approach was
employed, whereby studies were assessed at the study
level across four categories (random sequence generation,
allocation concealment, blinding of participants and person-
nel, and blinding of outcomes assessment) by a single
author (RR) and the results independently verified using
RobotReviewer (Tables 1 & 2).19 RoB assessments were not
performed for subanalyses of HHF-event trial data, or studies
assessing broader SGLT2i mechanisms (exploratory review),
and data from these studies were synthesized directly from
included papers into the review.
Searches of ongoing trials
We also searched ClinicalTrials.gov for ongoing or completed,
but unpublished trials of SGLT2is in patients with HF. The
publication status of trials identified by the ClinicalTrials.gov
searches was monitored beyond the cut-off date of the main
literature search to allow up-to-date inclusion of data from
large trials on effects of SGLT2is on HHF events, and trials
on the effects of SGLT2is on cardiac structure and function
in patients with HF (Figure 2).
Results
A Preferred Reporting Items for Systematic Reviews and
Meta-Analyses summary of the literature and ClinicalTrials.
gov searches is presented in Figure 2.
Randomized controlled trials evaluating effects
on hospitalization for heart failure events
All studies assessing the impact of SGLT2is compared with
placebo on HHF were deemed to have a low RoB (Table 1).
Type-2 diabetes mellitus and high cardiovascular risk
The EMPA-REG OUTCOME (empagliflozin) and CANVAS
(canagliflozin) trials were conducted in patients with T2DM
with high cardiovascular disease (CVD) risk, with or without
underlying CVD (Table 1).3,4 Both included major adverse
CV events [MACE; cardiovascular (CV) death, non-fatal myo-
cardial infarction (MI) or non-fatal stroke] as their primary
endpoint and reported significant relative risk reductions of
14% for this outcome with SGLT2i treatment compared with
placebo.3,4 Substantial reductions in the risk of HHF were
observed in both trials (35% and 33%, respectively).
Post hoc analyses of EMPA-REG OUTCOME data indicate
similar reductions in the risk of HHF with empagliflozin
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regardless of the following baseline characteristics: age; sex;
ethnicity; body mass index (BMI); glycated haemoglobin
(HbA1c), blood pressure, or uric acid levels; degree of kidney
function; medication use; CVD or HF risk; presence of periph-
eral artery disease or atrial fibrillation; and history of coro-
nary artery bypass grafting.20–32 Post hoc analyses of
CANVAS trial data reveal similar reductions in HHF risk with
canagliflozin regardless of baseline age, sex, BMI, HbA1c or
blood pressure levels, degree of kidney function or albumin-
uria, medication use, T2DM duration, or history of CVD.33–35
The DECLARE-TIMI 58 trial was the first to include a com-
posite of CV death or HHF as a primary endpoint. In addition,
the trial included patients with T2DM who had established
atherosclerotic CVD (41%) or were at high risk of atheroscle-
rotic CVD (59%) (Table 1).6 A significant 17% reduction in the
risk of the primary endpoint was reported for dapagliflozin
compared with placebo, in addition to a 27% reduction in
the risk of HHF.6 Notably, the co-primary endpoint of MACE
was numerically less but not significantly improved with
dapagliflozin in this trial (7% risk reduction vs. placebo).6
Figure 2 PRISMA flow diagram summarizing the search strategy. aPhase 1 trials and studies assessing PK and/or safety only were excluded. bIncludes
two studies also included in Table 1 (i.e. HHF: double-blind, placebo-controlled RCTs). Hence, the total number of studies across categories adds up to
67 rather than 65. AHF, acute heart failure; CF, cardiac failure; CHF, congestive heart failure; CV, cardiovascular; CVD, cardiovascular disease; HF, heart
failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HHF, hospitalization for heart failure;
MESH, Medical Subject Headings; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT, randomized controlled trial;
SGLT2, sodium–glucose cotransporter 2; SGLT2i, sodium–glucose cotransporter 2 inhibitor.
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The effects of dapagliflozin on HHF risk were not significantly
affected by baseline age, T2DM duration, presence of HF with
reduced ejection fraction (HFrEF), or history of MI, based on
subsequent post hoc analyses.36–39
Most recently, the VERTIS CV trial assessed MACE as its pri-
mary endpoint in patients with T2DM and established athero-
sclerotic CVD (Table 1).7 The primary endpoint was not met
based on a 3% reduction in the risk of MACE for ertugliflozin
compared with placebo. Nevertheless, confidence intervals
for this result still overlap with other studies.7 Also, despite
not meeting its primary endpoint, a 30% reduction in the risk
of HHF was observed. No post hoc analyses of the VERTIS CV
trial were identified at the time of our literature search.
Type-2 diabetes mellitus with chronic kidney disease
The CREDENCE trial included patients with T2DM and albu-
minuric CKD, and reported a 30% reduction in the risk of its
primary renal endpoint (end-stage renal disease, doubling of
serum creatine, or death from renal or CV causes) with
canagliflozin compared with placebo (Table 1).5 HHF risk was
also significantly reduced by 39% with canagliflozin.5 Post
hoc analyses of CREDENCE data suggest there were no signif-
icant associations between baseline kidney function or history
of CVD and the effects of canagliflozin on HHF risk.40,41
Heart failure with reduced ejection fraction with or without
type-2 diabetes mellitus
Two trials of SGLT2is have now been completed in patients
with HFrEF without the presence of T2DM as an inclusion cri-
terion, both of which used a composite primary endpoint of
CV death or worsening HF (Table 1).8,9 In the DAPA-HF trial,
treatment with dapagliflozin significantly reduced the risk of
the primary outcome by 26% compared with placebo, and
the exploratory endpoint of HHF was reduced by 30%.8 Nearly
identical results were obtained with empagliflozin treatment
in the EMPEROR-Reduced trial, with significant risk reductions
of 25% and 31% observed for the primary endpoint and HHF,
respectively, compared with placebo.9 Based on post hoc anal-
yses, the effects of dapagliflozin on HF do not appear to be in-
fluenced by baseline age, presence of T2DM, left ventricular
(LV) ejection fraction, Kansas City Cardiomyopathy Question-
naire score, or background HF medication or diuretic use.42–
48 No post hoc analyses of EMPEROR-Reduced were identified
at the time of our literature search.
Summary, implications, and future trials in heart failure
Sodium–glucose cotransporter 2 inhibitors exhibit remark-
able consistency in terms of reducing HHF risk across trial
populations (range: 27–39%; low RoB for all studies).3–9 Cru-
cially, with the results of the DAPA-HF and EMPEROR-
Reduced trials, these benefits have been confirmed to extend
to patients with established HFrEF regardless of T2DM
status,8,9 thus shifting the role of SGLT2is from prevention
to active treatment of HFrEF.
A key question remaining is whether SGLT2is also benefit
patients who have HF with preserved ejection (HFpEF), for
which there are no treatment options strongly recommended
in clinical guidelines.49 It is likely that the EMPA-REG OUT-
COME trial included a significant proportion of patients with
HFpEF.3 Furthermore, results from the SOLOIST-WHF trial in-
vestigating the dual SGLT1 and SGLT2 inhibitor sotagliflozin in
patients with diabetes and recent worsening HF demon-
strated a significant 33% reduction in the relative risk of CV
death, HHF, and urgent visits for HF, which was maintained
in the subgroup of patients with HFpEF.50 These findings
offer hope of similar results from the ongoing EMPEROR-
Preserved and DELIVER trials assessing the effects of
empagliflozin and dapagliflozin, respectively, on CV death
and HHF in patients with HFpEF (primary completion due first
half of 2021) (Table 3).
Of note, both the DAPA-HF and EMPEROR-Reduced
trials also reported significantly improved Kansas City
Cardiomyopathy Questionnaire scores (indicating improved
patient-reported health status) with SGLT2i treatment
compared with placebo in patients with HFrEF.8,9 Several tri-
als will soon provide further insights into the effects of
SGLT2is on overall health status and quality of life in patients
with HFrEF (DETERMINE-Reduced, EMPERIAL-Reduced, and
CHIEF-HF) and HFpEF (DETERMINE-Preserved, EMPERIAL-
Preserved, and CHIEF-HF) (Table 3), providing a more
in-depth picture of the benefits of these drugs beyond CV
death and HHF.
Since the date of our literature search, results of the
DAPA-CKD study in patients with CKD with or without
T2DM have also been reported. A significant 39% reduction
in the relative risk of the composite endpoint of a sustained
decline in estimated glomerular filtration rate of at least
50%, end-stage renal disease, or death from renal or CV
causes was observed with dapagliflozin compared with
placebo in this study, which was similar in patients with or
without T2DM.51 In addition, there was a significant 29%
reduction in the secondary composite endpoint of CV death
or HHF (HHF not reported separately).51 Primary completion
of the EMPA-KIDNEY trial, assessing empagliflozin in patients
with CKD without T2DM, is due in 2022 (Figure 1).
Randomized controlled trials assessing effects on
cardiac structure and function
Left ventricular structure and function
All studies assessing the impact of SGLT2is compared with
placebo on LV structure and function were deemed to have
a low RoB (Table 2).
The DAPA-LVH study included 66 patients with T2DM, LV
hypertrophy, and controlled blood pressure who were ran-
domized to receive either dapagliflozin 10 mg or placebo
daily for 12 months.10 The primary outcome was the change
4102 R. Rasalam et al.
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in LV mass, an indicator of cardiac hypertrophy, assessed by
cardiac magnetic resonance imaging. Dapagliflozin reduced
LV mass significantly more than placebo in this trial (Table 2).
Cardiac hypertrophy was also assessed in the EMPA-HEART
study, in which 97 patients with T2DM and coronary artery
disease (CAD) were randomized to receive empagliflozin
10 mg or placebo daily for 6 months.11 This trial assessed
the change in LV mass (indexed to body surface area) as its
primary outcome, which was found to be significantly
reduced with empagliflozin compared with placebo (Table 2).
In the REFORM trial, 56 patients with T2DM and HF with
LV systolic dysfunction were randomized to receive
dapagliflozin 10 mg or placebo daily for 52 weeks.12 No signif-
icant differences were reported for the primary outcome of
change in LV end-systolic volume as assessed by cardiac mag-
netic resonance imaging (Table 2).
Change in LV end-systolic volume (indexed to body surface
area) was also assessed as the primary outcome in the SUGAR-
DM-HF trial, which randomized 105 patients with HFrEF and
T2DM or prediabetes to receive empagliflozin 10 mg or
placebo daily for 9 months.17 LV end-systolic volume was
reduced to a significantly greater extent with empagliflozin
compared with placebo in this trial (Table 2).
Finally, in the EMPA-TROPISM trial, change in LV
end-diastolic volume was assessed as the primary endpoint
in 84 non-diabetic patients with HFrEF who were randomized
to receive empagliflozin 10mg or placebo daily for 6months.16
This endpoint was significantly reduced in patients receiving
empagliflozin compared with those who received placebo
(Table 2).
N-terminal pro B-type natriuretic peptide as a marker of car-
diac stress
Secretion of N-terminal pro B-type natriuretic peptide (NT-
proBNP) by cardiomyocytes in response to myocyte stretching
is a marker of stress due to increased cardiac filling pressure.52
All studies assessing the impact of SGLT2is compared with pla-
cebo on NT-proBNP levels were deemed to have a low RoB
(Table 2).
In the EMPA-RESPONSE trial, 80 patients admitted for
acute decompensated HF were randomized to receive
empagliflozin 10 mg or placebo daily for 30 days.13 A primary
outcome of this study was the change in NT-proBNP after
4 days of treatment, which was not found to be significantly
different between treatment groups (Table 2).
Change in NT-proBNP level was also assessed as a primary
outcome with empagliflozin treatment in the EMPIRE HF
study.14 In this trial, 190 patients with HFrEF were random-
ized to receive empagliflozin 10 mg or placebo daily for
12 weeks. The change in mean NT-proBNP level from baseline
to 12 weeks was not significantly different between treat-
ment groups (Table 2).
In the DEFINE-HF trial, change in NT-proBNP level was
assessed as a primary outcome in 263 patients with HFrEF
after randomization to 10 mg dapagliflozin or placebo
daily for 12 weeks.15 No significant difference between
dapagliflozin and placebo was observed for this measure
(Table 2).
In the DAPA-HF and EMPEROR-Reduced trials, changes in
NT-proBNP level were included as exploratory outcomes in
patients with HFrEF.8,9 Data from these trials indicated
significantly reduced NT-proBNP with SGLT2i treatment
compared with placebo after 8–12 months (Table 2).
Summary, implications, and future trials in heart failure
Evidence from small, long-term (6–12 month) trials in
patients with T2DM, with concomitant LV hypertrophy or
CAD,10,11 and in patients with HFrEF with and without
diabetes,16,17 indicate that SGLT2i treatment may help to
reverse adverse LV remodelling (low RoB for all studies).
Indeed, to date, only the REFORM trial (low RoB) has
included such a measure as its primary outcome and failed
to detect a significant effect.15 This may reflect differences
in the population, such as inclusion of asymptomatic
patients with New York Heart Association class I HF (vs.
II–III in the other HF studies), or be due merely to chance,
particularly given these are small trials. Several SGLT2i trials
including measures of cardiac structure and function in
patients with HF are nearing completion (EMBRACE-
HF, ERTU-GLS, STADIA-HFpEF, VERTICAL, EMMED-HF, &
NCT04304560) (Table 3).
None of the three trials assessing short-term changes
(4 days to 12 weeks) in NT-proBNP levels in patients with HF
detected a significant effect with SGLT2i treatment (low RoB
for all studies).13–15 However, larger, long-term (8–12 month)
trials have identified significant decreases in NT-proBNP with
SGLT2i treatment compared with placebo (low RoB for both
studies).8,9 In addition, changes in NT-proBNP were assessed
as secondary outcomes in both SUGAR-DM-HF and EMPA-
TROPISM and were significantly reduced with SGTL2i treat-
ment compared with placebo.16,17 Reduced NT-proBNP may
thus be a long-term consequence of SGLT2i treatment, or
larger sample sizes may be required to detect early changes.
Several larger trials are assessing early NT-proBNP changes
as secondary outcomes in patients with HF (EMPULSE,
NCT04249778, and PRESERVED-HF) (Table 3).
Potential mechanisms of sodium–glucose
cotransporter 2 inhibitor efficacy in heart failure
The following section is an exploratory, narrative synthesis of
RCT-derived data relating to mechanisms by which SGLT2is
may improve HF outcomes. RoB assessments were not
performed for studies in this section, and supplementary
literature is cited in places for additional context.
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Conventional cardiovascular disease risk factors
Reduced Hb1Ac levels with SGLT2i treatment do not account
for their ability to reduce HHF events. First, changes in Hb1Ac
to the degree observed with SGLT2i treatment in major
event-driven trials were relatively modest,3–9 and changes of
this scale do not lead to similar reductions in HHF with other
drugs. Second, although the HbA1c-reducing effects of
SGLT2is decline as renal function declines,53 reductions in HF
events were consistent across different baseline estimated
glomerular filtration rates.30,34,40,53
Sodium–glucose cotransporter 2 inhibitors have also been
consistently shown to reduce body weight and blood pres-
sure in addition to HbA1c levels in key trials3–9; however,
these effects also cannot fully account for reduced HF events
with SGLT2i treatment. In two post hoc analyses of
EMPA-REG OUTCOME data, simulation of the effects of
empagliflozin compared with placebo on conventional CVD
risk factors accounted for only 15% and 37% of the observed
reduction in HHF risk observed in patients with T2DM and
CVD.54,55
A plethora of mechanisms outside of changes in conven-
tional CVD risk factors have been proposed for how SGLT2is
may improve HF outcomes (Figure 3A). However, not all have
been the focus of RCT studies, which are reviewed in the fol-
lowing sections.
Haemodynamic changes
In a pooled analysis (N = 4533) of double-blind, RCT data in
patients with inadequately controlled T2DM and blood
pressure, the estimated plasma volume was significantly re-
duced with dapagliflozin 10 mg compared with placebo at
24 weeks.56 Blood plasma volume was also significantly re-
duced with canagliflozin 300 mg daily compared with placebo
at 1 week in a double-blind RCT in 36 patients with inade-
quately controlled T2DM and hypertension controlled with
renin–angiotensin–aldosterone system inhibitor therapy;
however, in contrast with the previous study, this effect was
largely attenuated at 12 weeks.57
Taken together, the above evidence suggests that haemo-
dynamic changes due to SGLT2i-induced diuresis may con-
tribute to their efficacy. However, this must be reconciled
with a lack of evidence for reduced mortality in patients with
HF treated with traditional diuretics. Modelling based on data
from an open-label, randomized study in healthy individuals
predicted a two-fold greater reduction in interstitial fluid
(IF) volume than in blood volume for dapagliflozin.58 In com-
parison, modelling data for bumetanide indicated a reduction
in IF volume that was only 78% of that observed for blood
volume.58 These data suggest greater effects with SGLT2i
treatment compared with diuretics on interstitial
congestion.58 A key prediction of this model is that larger
reductions in IF volume relative to blood volume may more
effectively relieve signs and symptoms of interstitial conges-
tion, and provide relief of elevated cardiac filling pressures
without the deleterious effects of excessive blood volume de-
pletion, such as reduced arterial filling and neurohormonal
activation.58 This prediction appears to have been borne
out in a subsequent double-blind, crossover RCT in which
14 days of empagliflozin 10 mg daily did not cause neurohor-
monal activation, despite causing natriuresis and decreases in
plasma blood volume.59 Notably, several ongoing trials are
assessing haemodynamic effects of SGLT2is in patients with
HFrEF (ELSI, ERADICATE-HF, DAPA-Shuttle1, VERTICAL, and
NCT04438213) (Table 3).
A recent double-blind RCT (RECEDE-CHF) investigating the
effects of empagliflozin 25 mg once daily on top of loop di-
uretic (furosemide) treatment found that this combination
significantly increased urine output compared with furose-
mide alone, without a significant increase in natriuresis after
6 weeks.60 Although small (N = 23), this trial partly allays fears
of an increased risk of volume depletion with combined
SGLT2i and loop diuretic use. Indeed, there now appear to
be numerous differences in the physiological effects of
SGLT2is compared with diuretics (Table 4).
Tissue sodium content
The effects of dapagliflozin treatment compared with placebo
on tissue sodium content at 6 weeks have been assessed in
59 patients with T2DM in a double-blind, crossover RCT.61
Tissue sodium content in the skin, but not muscle, was found
to be significantly reduced with dapagliflozin compared with
placebo, with no significant changes in water content ob-
served in either tissue.61 The ability of peripheral tissues to
sequester sodium is a critical assumption of the haemody-
namic model of differential volume regulation (IF vs. plasma
volume) proposed above for SGLT2is.58 In addition, increased
tissue sodium content has been independently linked to LV
hypertrophy in patients with CKD.62 It has also been hypoth-
esized that decreased renin–angiotensin–aldosterone system
activation with SGLT2is may decrease sodium-hydrogen ex-
changer 1 (NHE 1) activity in the heart, decreasing intracellu-
lar sodium and calcium to reduce cardiomyocyte death, as
well as inhibiting NHE3 in the kidneys with potential
renoprotective effects.63 Indeed, SGLT2i-driven inhibition of
NHE3 sodium reabsorption (along with direct inhibition of so-
dium and glucose reabsorption through SGLT2 and osmotic
diuresis coupled with peripheral sodium storage) was identi-
fied as a key mechanism required to explain benefits such as
reduced glomerular pressure, and reduced blood and IF vol-
ume, in a model-based analysis of clinical data.64 Effects of
dapagliflozin on tissue sodium are also being assessed in HF
in the DAPA-Shuttle1 and ELSI trials (Table 3).
Erythropoiesis
A mediation analysis found that increased haematocrit and
haemoglobin levels, and reduced uric acid levels, were the
most important mediators of reduced CV death with
empagliflozin treatment in the EMPA-REG OUTCOME trial.65
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Similarly, reduced uric acid levels, and increased erythrocyte
and haemoglobin levels, were identified as important media-
tors of the effects of canagliflozin on HF events in the CAN-
VAS trial programme, although haematocrit had a smaller
mediating effect in this study compared with the EMPA-REG
OUTCOME trial.65,66 Indeed, elevated haematocrit and/or
haemoglobin levels have been consistently observed with
SGLT2i treatment.3,8,9
Although reductions in plasma volume may contribute to
increased haematocrit and haemoglobin concentrations ob-
served with SGLT2i treatment, it has been observed that
the time course of changes in these variables does not
align.67 An alternative explanation may be that SGLT2i treat-
ment increases production of red blood cells. This hypothesis
was tested in 52 patients with T2DM randomized to
dapagliflozin or placebo treatment for 12 weeks. Significant
changes in markers indicative of enhanced erythropoiesis (in-
creased erythroferrone, decreased hepcidin, and transiently
increased erythropoietin) were observed in patients receiving
dapagliflozin compared with placebo in this study.68 The au-
thors of this study hypothesize that erythropoiesis may be
inhibited in a pro-inflammatory state.68 It has been argued
Figure 3 (A) Potential cardiorenal protective mechanisms that have been proposed to contribute to benefits observed with SGLT2is in patients with
HF. (B) Potential mechanisms that may account for early vs. later benefits observed with SGLT2is in patients with HF (adapted from McMurray et al.8).
Copyright © (2019) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society). AMPK, adenosine
monophosphate-activated protein kinase; HF, heart failure; HHF, hospitalization for heart failure; NHE, sodium-hydrogen exchanger; RAAS, renin–an-
giotensin–aldosterone system; SGLT2i, sodium–glucose cotransporter 2 inhibitor; SIRT1, sirtuin 1.
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separately that SGLT2is may prevent suppression of erythro-
poiesis through reduced renal metabolic ‘stress’ and inflam-
mation as a result of diuresis without sympathetic
activation.68 Kidney stress may also be reduced via
tubuloglomerular feedback due to SGLT2i-induced
natriuresis.67
Epicardial fat
We identified one RCT assessing the effects of SGLT2is on epi-
cardial adipose tissue (EAT) volume.69 In this open-label trial,
40 patients with T2DM and CAD were randomized to receive
dapagliflozin or conventional treatment for 6 months. A sig-
nificant reduction in EAT volume was observed with
dapagliflozin compared with placebo, and the reduction was
positively correlated with reductions in body weight and
the pro-inflammatory cytokine tumour necrosis factor-α.69
This is consistent with evidence that EAT expresses a patho-
genic profile of adipocytokines in patients with CVD.70 Accu-
mulation and inflammation of EAT also stimulates secretion
of leptin to promote fibrosis.71 Reduction of EAT with SGLT2is
may thus reduce cardiac inflammation and secretion of leptin
to reduce adverse cardiac remodelling.71
Inflammation
We identified a single, open-label RCT that assessed the ef-
fects of SGLT2is on inflammation.72 In this study, 102 patients
with T2DM and insulin resistance were randomized to receive
treatment with empagliflozin or placebo as add-on therapy
for 1 year.72 Significant reductions in remnant-like particle
cholesterol and high-sensitivity C-reactive protein, as well as
significantly reduced insulin resistance, were observed for
empagliflozin compared with placebo in this trial.72
Inflammation is a well-known contributor to CVD, and
patients with HF have elevated levels of pro-inflammatory
cytokines.73 Although drugs that specifically target inflamma-
tion have not performed well in previous HF clinical trials,
there is recent evidence that HF outcomes may be improved
in patients with HF who have a cardio-inflammatory
phenotype.73
Vascular function
In a double-blind RCT conducted in 81 patients with T2DM
and ischaemic heart disease, changes in flow-mediated
dilation and nitroglycerin-mediated vasodilatation were not
significantly different between dapagliflozin and placebo at
12 weeks,74 although consistent trends were observed
towards greater maintenance of these measures and reduced
markers of endothelial dysfunction with dapagliflozin.74
Secondary analysis of RCT data from 47 patients with T2DM
and high CVD risk who were randomized to receive
empagliflozin or placebo also found no significant difference
in endothelial function (reactive hyperaemia index) between
treatment groups.75 However, arteriolar remodelling was sig-
nificantly reduced, and retinal capillary flow was significantly
improved, with 6 weeks of dapagliflozin treatment compared
with placebo in 59 patients with T2DM in a double-blind,
crossover RCT.76 In a subsequent double-blind RCT conducted
by the same research group, 6 weeks of treatment with
empagliflozin was found to significantly improve various mea-
sures of aortic stiffness in 76 patients with T2DM compared
with placebo.77 These results are consistent with previous
findings from a pooled analysis of data from double-blind
RCTs assessing canagliflozin 100 mg or 300 mg daily
compared with placebo for 6 (N = 169) or 26 weeks
(N = 2313) in patients with T2DM, which also identified
significant reductions in markers of arterial stiffness.78
Sympathetic nervous system activity
Overactivation of the sympathetic nervous system is a key
characteristic of patients with HF and may contribute to poor
outcomes through the modulation of factors such as in-
creased vascular tone, contributing to macrovascular dys-
function and arterial stiffness,79 and cardiac activity that
may increase the risk of lethal ventricular arrhythmias and
sudden cardiac death.80 The sympathetic nervous system also
provides a potential link between the renoprotective effects
of SGLT2is and their CV benefits, because renal stress in-
creases systemic sympathetic activity via the central nervous
system.81 Evidence suggesting that SGLT2is may suppress
sympathetic activity comes from consistent decreases in
resting heart rate based on pooled RCT data,81 in contrast
to diuretics, which increase heart rate. We identified two
double-blind RCTs (EMBODY and EMPA-HEART) that assessed
the impact of SGLT2i treatment on sympathetic cardiac
activity. No significant differences in heart rate variability
(HRV) measures, used to assess cardiac sympathetic activity,
Table 4 Physiological effects observed with SGLT2is and diuretics




Uric acid ↓ ↑
LDL cholesterol ↔ ↑
Plasma glucose ↓ ↑
Haematocrit ↑ ↔
Heart rate ↓ ↑
Systolic blood pressure ↓ ↓
Intravascular volume ↓ ↓
Interstitial volume ↓ ↔
Myocardial infarction ↔ ↔
Stroke ↔ ↓
eGFR ↓ then ↔ ↓
Intraglomerular pressure ↓ ↔
Tubuloglomerular feedback ↑ ↔
Renin/angiotensin II ↓ ↑
Aldosterone ↓ ↑
Sympathetic tone ↓ ↑
Arginine vasopressin ↔ ↑
eGFR, estimated glomerular filtration rate; LDL, low-density lipo-
protein; SGLT2i, sodium–glucose cotransporter 2 inhibitor.
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were observed in 105 patients with MI and T2DM treated
with empagliflozin 10 mg daily for 24 weeks compared with
those who received placebo.82 HRV measures did, however,
decrease significantly from baseline with empagliflozin, but
not with placebo.82 HRV measures were also not significantly
altered after 6 months of treatment with empagliflozin 10 mg
daily compared with placebo in 66 patients with T2DM and
CAD in the EMPA-HEART study, with the exception of a signif-
icant reduction in the standard deviation of normal to normal
intervals.83 The statistical significance of changes from base-
line in HRV measures observed within treatment groups
was not assessed in this study.83 Further trials are needed
to establish the relevance of this mechanism, particularly in
patients with HF.
Cellular energetics
There has been substantial interest in the ‘ketone hypothesis’,
which proposes that ketogenesis induced by SGLT2is may
have favourable effects by providing an efficient fuel, in the
form of ketone bodies, that can boost the function of the
stressed heart in patients with HF.84 More recently, the oppo-
site of this hypothesis was proposed, in which SGLT2is are
suggested to induce a protective ‘dormancy’ state, possibly
through activation of adenosine monophosphate-activated
protein kinase/sirtuin 1 signalling.85,86 At least two double-
blind RCTs in patients with T2DM that were identified by
our searches support the notion of increased circulating ke-
tones with SGLT2i use compared with placebo [dapagliflozin
after 2 weeks (N = 18)87 and empagliflozin after 4 weeks
(N = 60)88]. However, a study in a hypertensive HF rat model
showed that empagliflozin was associated with reduced myo-
cardial ketone body use, suggesting that increases in circulat-
ing ketone levels may be a secondary phenomenon.89 The
relative merits of the opposing ‘ketone’ and ‘dormancy state’
hypotheses, which have been the subject of intense debate,
are better discussed in detail elsewhere.86 Regardless, hy-
pothesis-driven RCTs supporting any firm conclusions are lack-
ing, and given the potential importance of this mechanism,
the number planned trials investigating aspects of
myocardial energetics in patients with HF taking SGLT2is
(EMPA-VISION and EMMED-HF) appears relatively small (Ta-
ble 3).
Finally, in a study that analysed urine and plasma samples
from a 6 -week, double-blind, RCT of dapagliflozin in 31 pa-
tients with T2DM and elevated urine albumin levels, nine of
13 urine metabolites linked to mitochondrial metabolism
were elevated compared with placebo, while none were ele-
vated in plasma. These findings suggest that SGLT2is may im-
prove renal cell mitochondrial function.90
Summary, implications, and future trials in heart failure
It is helpful to consider proposed SGLT2i mechanisms in
terms of those that may account for the early separation of
SGLT2i and placebo HHF event curves at approximately 0–
3 months, vs. further separation that seems to occur at later
stages of treatment (Figure 3B). It is well recognized that in-
terstitial congestion/fluid overload is associated with worse
outcomes in patients with acute HF.91 The early benefit of
SGLT2i therapy may therefore relate to haemodynamic ef-
fects with natriuresis that is not accompanied by blood vol-
ume contraction,58 neurohormonal activation, or electrolyte
imbalance.59 Ketogenesis, if found to be a clinically relevant
mechanism of SGLT2i efficacy, could also have early benefits.
The reversal of adverse ventricular remodelling, among other
possible effects (Figure 3B), may help to account for
long-term SGLT2i benefits.
Although SGLT2is clearly have pleiotropic effects, not all
mechanisms are likely to contribute equally to their success
in HF. The consistency of the effects on HHF across trial
populations and trial subgroups hints at a subset of key
mechanisms that can operate across disease states, with
disease-state-specific effects accounting for some of the
variation in efficacy between populations.
Conclusions and future directions
Sodium–glucose cotransporter 2 inhibitors consistently
reduce HHF rates in clinical trials,3–9 including in patients with
established HFrEF and CKD, regardless of T2DM status,8,9 and
they are likely to also be effective in patients with HFpEF. RCT
data also support reversal of adverse LV remodelling as an ef-
fect of SGLT2i treatment that contributes to improved HF
outcomes. However, the magnitude of this contribution is un-
known, as is the contribution of other glucose-independent
SGLT2i mechanisms. Several intriguing and convincing
hypotheses have been proposed, but hypothesis-driven RCT
data are sparse.
A limitation of this review is that our assessment of
broader SGLT2i mechanisms was exploratory and may thus
be more prone to bias. Conversely, a strength of this section,
particularly in comparison with previous reviews, is that it
focused primarily on systematically identified RCT data. An-
other limitation of this review is that ongoing SGLT2i trials
registered in databases other than ClinicalTrials.gov may have
been missed. We also summarized ongoing SGLT2i trials in
patients with HF only, for practical reasons, and to maximize
relevance. However, mechanistic insights will (and have) also
come from ongoing studies in patients without HF, which are
not captured here. Despite these limitations, we believe this
review constitutes a rigorous and up-to-date assessment of
the field.
A position paper from the European Society of Cardiology
recently endorsed the use of dapagliflozin and empagliflozin
in symptomatic patients with HFrEF already receiving
guideline therapy, regardless of the presence of T2DM, based
on their efficacy profile and data indicating no excess
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risk of renal adverse events, volume depletion, severe
hypoglycaemia, fractures, amputations, or Fournier’s
gangrene.92 Nevertheless, owing to their origins (Figure 1),
the perception of SGLT2is as merely glucose-lowering
agents remains a communication challenge. At worse, this
perception may lead to discontinuation in patients in whom
negligible glycaemic effects are observed. Continued educa-
tion around the glucose-independent benefits of SGLT2is is
thus of paramount importance to maximizing patient care,
even if a sound mechanistic framework is currently lacking.
Upcoming trial results are likely to provide further clarity
regarding the efficacy and mechanistic profiles of SGLT2is.
Further research into SGLT2i mechanisms will offer new in-
sights into the pathophysiological mechanisms contributing
to disease progression in HF, and the nuanced functions of
the kidney, potentially yielding novel drug targets for both
CKD and HF.
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